Treprostinil is a stable synthetic analog of prostacyclin (prostaglandin PGI2), an IP receptor agonist used clinically for the treatment of pulmonary arterial hypertension. It is a potent vasodilator with antithrombotic, antiproliferative and anti-inflammatory properties.
Treprostinil elicits a longer half-life when compared with iloprost. It mediates inhibition of transforming growth factor-? (TGF-?) and nuclear factor-?B (NF-?B) signaling pathways. Treprostinil effectively reduces right ventricular systolic pressure and inhibits the recruitment of circulating fibrocyte.